Objective: We aimed to estimate from a societal perspective the 1-year and lifetime direct and indirect costs of traumatic brain injury (TBI) for New Zealand (NZ) in 2010 projected to 2020.
Results: In 2010, 11,301 first-ever TBI cases were estimated to have occurred in NZ; total firstyear cost of all new TBI cases was estimated to be US $47.9 million with total prevalence costs of US $101.4 million. The average cost per new TBI case during the first 12 months and over a lifetime was US $5,922 (95% confidence interval [CI] $4,777-$7,858), varying from US $4,636 (95% CI $3,756-$5,561) for mild cases to US $36,648 (95% CI $16,348-$65,350) for moderate/severe cases. Because of the unexpectedly large number of mild TBI cases (95% of all TBI cases), the total cost of treating these cases is nearly 3 times that of moderate/severe. The total lifetime cost of all TBI survivors in 2010 was US $146.5 million and is expected to increase to US $177.1 million in 2020.
Conclusion:
The results suggest that there is an urgent need to develop effective interventions to prevent both mild and moderate/severe TBI. Neurology ® 2014;83:1645-1652 GLOSSARY BIONIC 5 Brain Injury Outcomes New Zealand in the Community; CI 5 confidence interval; GCS 5 Glasgow Coma Scale; ICD-10 5 International Classification of Diseases, tenth revision; MOH 5 Ministry of Health; NMDS 5 National Minimum Dataset; NZ 5 New Zealand; TBI 5 traumatic brain injury; WIES 5 Weighted Inlier Equivalent Separations. Traumatic brain injury (TBI) is the leading cause of long-term disability in children 1 and young adults, 2 having a significant impact on the person, their family, caregivers, and society. 3 A recent TBI population-based incidence and 1-year outcomes study (Brain Injury Outcomes New Zealand in the Community [BIONIC]) 2 found that the incidence of TBI in the population is far greater than previously estimated.
Previous authors have concluded that the financial burden of TBI is substantial, [4] [5] [6] with hospitalization costs accounting for 60% to 70% of overall direct medical costs. [7] [8] [9] [10] [11] Previous studies are limited because they focused primarily on hospitalized individuals. 12 These patients tend to have the most severe injuries. Cases of mild TBI (defined by Glasgow Coma Scale [GCS] score $13) constitute 95% of all cases 2 and frequently are not hospitalized. By focusing on hospitalized cases, previous studies might overstate the average cost per individual but understate the total cost of TBI to society. A further limitation of previous studies is the lack of inclusion of nonhospitalization costs of TBI.
This study utilized data from the population-based BIONIC Study in combination with electronic hospital records, official death records, and self-reported health services usage. The objective was to estimate the societal cost of TBI in the first year, and lifetime direct and indirect costs of TBI by severity levels for New Zealand (NZ) in 2010 projected to 2020.
METHODS Estimating NZ TBI incidence and prevalence. The BIONIC Study used multiple overlapping sources of information to capture all new TBI cases (fatal/nonfatal, hospitalized/nonhospitalized) across all ages and all TBI severities (mild, moderate, severe) in urban and rural residents of Hamilton and Waikato Districts (population approximately 173,000) from March 1, 2010 to February 28, 2011. All TBI cases consenting to participate in the study (n 5 725; 53%) were followed up over 12 months post-TBI. Further details of the methodology, diagnostic criteria, and main incidence results of the study are reported elsewhere. 2, 13 Where possible, all surviving participants were interviewed at baseline and 1, 6, and 12 months postinjury. TBI severity was defined using standard definitions [14] [15] [16] (see e-Methods on the Neurology ® Web site at Neurology.org). Baseline information included demographics, medical history, and place of residence before TBI. One-month assessment documented initial acute treatment. At 6 and 12 months, participant's use of outpatient, rehabilitation and home care services, and health status were recorded. Information on emergency department presentations and hospital admissions was obtained from the National Minimum Dataset (NMDS), NZ Ministry of Health (MOH). The NMDS includes all presentations and admissions to public or private hospitals in NZ and these are linked to individuals via National Health Index numbers. 17 Only services funded in whole or part by District Health Boards and the Accident Compensation Corporation, a no-fault personal accident insurance cover (health funders in NZ), were available.
Prevalence was modeled 18 from data on incidence, remission, and mortality using multistate life table methods. 19, 20 Compared with the total NZ population census (base 2006) information, the Hamilton and Waikato populations have demographic and social characteristics that are reflective of NZ. TBI incidence and prevalence were estimated for NZ in the reference year and then projected to 2020, assuming similar trends in TBI prevalence to that estimated for 2010. Cost of illness model. An incidence-based cost of illness model (bottom up approach) was developed to estimate the economic cost of TBI in NZ. All costs are expressed in US dollars using purchasing power parity conversion rate of 1.49 (NZ$). 21 Costs. The types and unit costs of each health service are shown in table e-1. The cost analysis included direct health care costs (e.g., hospitalizations, outpatient rehabilitation services), indirect costs (e.g., productivity loss for person with TBI), and out-ofpocket expenses (e.g., aids, home modification).
Hospital inpatient and outpatient costs. TBI hospitalizations were confirmed by ICD-10 codes S06.0 to S06.9. NZ has a national health service with government-run hospital care available free of charge. There is one major hospital in the Waikato Region that provides care for the region 22 (see e-Methods for background of NZ health system). The cost of hospital care is assessed from hospital reimbursements from the MOH. Hospitalization costs were determined using weighted discharge value (i.e., Weighted Inlier Equivalent Separations [WIES]) for all NMDS events by the MOH. 17 The national price for financial year 2010/2011 per WIES was US $2,959.98. 23 Because the hospital services are provided by the publicly owned District Health Boards (not patient charges), the costs are internal weighted estimates (based on Disease Related Groups and length of stay) of the cost of each type of care. WIES cost weight includes medical costs, ward stay, medication, laboratory tests, diagnostic imaging, and nursing and other ward staff.
Community and home support. Although most formal care for home support services is funded by the state, providers contracted with the government provide the bulk of services. As such, no accurate information exists on individual charges for TBIrelated community and home support. To estimate the cost of these services, a resource-based costing approach was used where a common price was applied to each resource (e.g., cost per hour per therapist).
Number of visits to therapists (i.e., visiting nurses, physiotherapists, medical specialists, occupational therapist, speech therapist, general practitioners, counselors, psychologists, and social workers) over the month before each BIONIC assessment (i.e., 1, 6, and 12 months post-TBI) was assessed via patient and significant other questionnaires. The cost of therapy visits was estimated by multiplying visit number by resource unit cost. Similarly, hours of home support (home help and personal care) were estimated using BIONIC follow-up questionnaire data by multiplying the number of hours provided by the current cost of care for the service (in US$, 2010). Finally, the cost of basic maintenance and home modification support resulting from TBI was estimated by combining information obtained from the patient, family, or caregiver survey responses with current market prices.
Direct costs included hospitalization and emergency department visits, regardless of whether they resulted in an admission, and the number of therapy visits provided to individuals living at home included home help and personal care services. All categories were summed together to estimate average cost per case.
Lifetime direct costs associated with TBI. At each follow-up, BIONIC participants were questioned about direct medical resources used relating to their TBI. At 12 months post-TBI, the proportion of participants identified as having a moderate to severe disability (defined by the Glasgow Outcome Scale) was sourced from the BIONIC dataset and used to determine the probability of needing ongoing health resources (i.e., after 12 months). If an individual had residual disability (including mild or moderate/severe TBI) at 12 months, this was assumed to persist for a lifetime. A weighted average cost for adults and children identified as having a moderate to severe TBI was then calculated (i.e., average direct cost per case 3 probability of having a moderate/severe disability). The discounted lifetime health care costs (see statistical analysis section) occurring in each year were then summed together with the first-year costs.
Productivity loss. First, production losses within 12 months of injury were estimated only for a friction period after the loss of paid work. 24,25 Short-term productivity loss was valued using a friction cost approach, which assumes that individuals absent from paid employment because of disablement or early mortality will be replaced after a specific time period. 25 In line with previous cost of illness studies, a friction period of 3 months was used. 26 Second, at 12-month follow-up, the proportion of participants reporting a decrease in income was identified. The value of time lost from employment or productive activity up to age 65 years was estimated for adults in paid workforce and adults in unpaid productive activity before injury. Costs of productivity were estimated using reported loss of income from BIONIC case record forms combined with Statistics NZ data on average weekly earnings linked to occupation for those who were in the paid workforce. 27 Because of lack of accurate information, cost of informal care (including care for childhood TBI) or compensation was not included in our analysis.
Statistical analysis. SPSS statistics version 20 (IBM Corp., Armonk, NY) was used to analyze data. Costs per person and total cost for NZ are presented as means with 95% confidence intervals (CIs) for a given year and over a lifetime. Significance of differences between the costs of mild and moderate/severe TBI was tested using t tests and Wilcoxon rank sum tests. Significance level was set at p , 0.05 (2-sided) . Multivariate probabilistic uncertainty analyses including a 5,000 replications Monte Carlo simulation were undertaken using @Risk software version 6 (2013; Palisade Corporation, Ithaca, NY) to test the uncertainty of the estimates and strength of the results. Calculation of sensitivity analysis used gamma distributions for cost estimates. A discount rate of 3.5% was used for lifetime cost projections as recommended by the NZ Treasury 28, 29 and PHARMAC (NZ Pharmaceutical organization). 30 RESULTS Incidence and prevalence of TBI in NZ. In 2010, 11,301 first-ever TBI cases were estimated to have occurred in NZ, 57% of whom were male. The majority (75%) were younger than 35 years. Taken together, the total number of patients with TBI in NZ (including prevalent cases) was estimated to be 527,388. In 2020, the number of first-ever cases was estimated to increase to 13,591 and the number of prevalent cases (period prevalence) was expected to increase to 641,104 cases. study and the high proportion of cases not needing acute hospitalization.
Average first-year cost by TBI severity. The per-person (first-year) cost estimates reported here are much lower than those reported in previous studies. 5, 6, 10, 11, 31, 32 This may be because previous studies focused primarily on patients who were hospitalized for their TBI. These patients tend to have more severe injuries and, as a result, the highest direct Accumulated first-year costs according to cost category for traumatic brain injury Abbreviation: TBI 5 traumatic brain injury.
and indirect health care costs. By contrast, the present results are based on the first large prospective population-based study investigating TBI incidence and outcomes in hospitalized and nonhospitalized patients with TBI. 2, 13 Information on the total cost and pattern of health services usage post-TBI can be used for health services planning, including helping hospitals and the MOH (1) anticipate and budget for the health care services needed to detect and treat TBI, (2) assess whether new methods of testing or treating are cost effective, and (3) identify disparities and inequities in accessing and delivery of health services post-TBI. The cost per case of TBI can also inform decisions regarding costeffective interventions to reduce TBI by providing information on the costs that can be averted through prevention activities.
There are a number of caveats regarding the interpretation of the results. First, cost estimates only report the services that people use. People with TBI that is untreated or who have access to only limited health care services and compensation beyond the Table 4 Results of uncertainty analyses on cost estimates (US$ 2010) acute injury phase will have spuriously lower reported costs. This is true in NZ where marginalized groups have disproportionately lower access to health care services. Further study is needed to identify the additional community and home services that are needed by those who experience TBI. Second, accurate information on some funded health services (e.g., primary care, home/vehicle modification, vocational rehabilitation) is difficult to obtain. Although there are electronic records containing this information, there are no central, accessible data with complete health services usage. Given the access to nationwide hospitalization data, it is likely that any missed cases were mild rather than moderate or severe. Third, extrapolating costs from one region to the entire county is subject to error, particularly if differences in lifestyles, clinical practices, and treatment options affect rates and health services usage. Fourth, our methodology did not provide accurate estimates of total caregiver time and effort dedicated to supporting injured persons. Caregiver time and expenses are clearly significant costs to those living at home, but estimating them requires a different methodology than used in the current study. Fifth, the lifetime cost estimates, based on short-term data, should be viewed as only approximate and highlight the need for a longitudinal study of the long-term effects of TBI including cognitive decline and dementia. Taken together, the uncertainty caused by these factors may underestimate the costs of TBI in NZ and care should be taken when extrapolating the results to other counties.
In conclusion, the findings suggest that the economic burden of TBI is significant and that improved prevention and treatment strategies are warranted. Significant cost savings may be achieved by preventing TBI, particularly for high-cost individuals. Furthermore, given the high number of mild TBI cases, public health officials should identify strategies to reduce incidence of mild injuries. The results also suggest that interventions to improve detection and treatment outcomes will be associated with significant cost savings. Further studies are required to identify cost-effective strategies for prevention, detection, and treatment, and to explore the impact of TBI on families and caregivers.
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